Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 1999

View Archived Issues

Alliance announces agreement with FDA for phase III trials of blood substitute product

Allergan enters marketing agreement with McNeil for ophthalmic ofloxacin

Colazide approved for ulcerative colitis maintenance in Europe

Biomira updates development activites at recent healthcare conference

MedImmune licenses catalytic antibody against cocaine

Novo Nordisk's liquid growth hormone approved in the E.U.

Neurocrine Biosciences and Arena establish research collaboration

Cell Genesys reacquires product rights for AIDS gene therapy

Japanese lab prepares depsipeptide apolipoprotein E production promoters

Research at Kyorin leads to potent, nontoxic and water-soluble camptothecin derivative

CXCR1/CXCR2 receptor antagonists a focus of research at Warner-Lambert

Bacterial histidine kinase inhibitors in the Ortho-McNeil pipeline

Newly discovered metabolite of sinomenine with more potent immunosuppressive activity

Positive AMPA receptor modulators developed and evaluated at NeuroSearch

Presentation of preliminary phase II results with DepoMorphine at World Congress on Pain

New fentanyl-like opioid analgesic profiled at recent European congresses

FDA approves Rapamune for rejection prevention in renal transplantation

Amrad presents first data on AM-336 and AM-543 at international congress

Abbott terminates license agreement for LJP-394; La Jolla focuses on Toleragen candidates

NK1 receptor antagonist from Servier proves effective in models of chronic neuropathic pain

Pharmacological characterization of new sodium channel blocker: RS-132943

New, orally active EP1 receptor antagonist assessed for effects in pain models

AstraZeneca seeks FDA approval of Toprol-XL as heart failure treatment

Abbott designs second-generation farnesyltransferase inhibitors with promising activity

Myriad Genetics establishes strategic alliance with Galileo Genomics

FDA advisory panel votes against recommending approval for Evacet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...